Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced a remarkable achievement with $186.0 million in net revenue for the third quarter ending September 30, 2024. This milestone …
Harmony Biosciences Reports Record Revenue and Plans Expansion in CNS Treatments Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is set to announce its third quarter 2024 financial results on Tuesday, October 29, 2024, prior to the opening of …
Get Ready for Harmony Biosciences’ Q3 2024 Financial Results Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is set to showcase its promising late-stage pipeline during an Investor Day event scheduled for October 1 in New York City. …
Harmony Biosciences to Unveil Promising Late-Stage Pipeline at Investor Day Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will actively participate in two major investor conferences this September.
Harmony Biosciences Set to Engage at Key Investor Conferences Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported a 29% increase in net revenue for the quarter ended June 30, 2024. The company highlighted progress in its …
Harmony Biosciences Reports Q2 Growth and Expands Pipeline Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is set to reveal its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets …
Harmony Biosciences to Announce Q2 Financial Results Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) recently denied a Citizen Petition filed by a short seller. The …
FDA Denies Petition Challenging Safety and Efficacy of Harmony Biosciences’ Drug Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets. The …
FDA Approves Harmony Biosciences’ WAKIX for Pediatric Narcolepsy Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) recently unveiled promising data at the annual meeting of the Associated Professional Sleep Societies, “SLEEP 2024.” The data from a Phase 2 …
Harmony Biosciences Presents Promising Data on Pitolisant for Myotonic Dystrophy Type 1 Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced its management team will join a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event …
Harmony Biosciences to Participate in Goldman Sachs Healthcare Conference Read More